SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer
Our findings suggest that SLC15A2 serves as a promising prognostic biomarker in PCa, enabling accurate risk stratification for BCR. This insight may contribute to the advancement of personalized treatment strategies for PCa.
Authors
- Weide Zhong (ORCID: https://orcid.org/0000-0002-0430-2845)
- Zhihao Zou
- Jianming Lü (ORCID: https://orcid.org/0000-0002-3794-641X)
- Zhenguo Liang
- Wenjun Yin (ORCID: https://orcid.org/0000-0003-0366-5174)
- Jundong Lin (ORCID: https://orcid.org/0000-0001-7068-2172)
- Jianheng Ye
- Ping He (ORCID: https://orcid.org/0000-0002-8005-8119)
- Zhenjie Wu (ORCID: https://orcid.org/0000-0002-6487-5207)
Institutions
- Macau University of Science and Technology (MO)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou First People's Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.21873/anticanres.17402
- Citations
- 2
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.57